Compound management

Last updated

Compound management in the field of drug discovery refers to the systematic collection, storage, retrieval, and quality control of small molecule chemical compounds used in high-throughput screening and other research activities to identify hits that can be developed into candidate drugs.

Contents

Drug discovery depends on methods by which many different chemicals are assayed for their activity. These chemicals are stored as physical quantities in a chemical library or libraries which are often assembled from both outside vendors and internal chemical synthesis efforts. These chemical libraries are used in high-throughput screening in the drug discovery hit to lead process. [1]

The chemical libraries in larger pharmaceutical companies are a critical part of the discovery process. These chemicals are stored in environmentally controlled conditions in small or large containers, often labeled with codes that pass back into a database. Each chemical in the storage bank must be monitored for shelf life, quantity, purity and other parameters, and its banked location. In some companies, the compounds can also include biological compounds, such as purified proteins or nucleic acids. The management of these chemical libraries, including renewal of outdated chemicals, databases containing the information, robotics often involved in fetching chemicals, and quality control of the storage environment is called Compound Management or Compound Control. Compound Management is often a significant expense, as well as career for one or more individuals who manage a chemical library at a research site. [2]

There are many books and journal articles devoted entirely or in part to compound management. [3] It has become a critical technological component for high-throughput screening and chemical genomics. There are great challenges to be faced in the necessity of compound management, which are being surmounted by concerted efforts in the public and private domain. [4] In 2008, authors at the National Institutes of Health's Chemical Genomics Center have released a paper showing the necessity of a highly automated, reliable and parallel compound management platform, in order to serve over 200,000 different compounds. [5]

In short, Compound Management requires inventory control of small molecules and biologics needed for assays and experiments, especially in high-throughput screening. It utilizes knowledge of chemistry, robotics, biology, and database management. The manager must also be acutely aware of safety standards in the handling and storing of radioactive, volatile, flammable and unstable compounds. Often, in large pharmaceutical companies, the chemical and biological compounds contained in compound libraries can number in the millions, making compound management and compound control important contributors to research and drug discovery.

Outsourcing

Because of the significant expenses and infrastructure required for accurate compound management (space requirements, robotics, IT support, analytical support, etc.) many companies choose to outsource this function to a company that specializes in this arena. It is important to work with a company that has significant experience in compound management due to the complexity of tracking not only inventory data, but also compound location, storage conditions, and compound integrity. This experience also is of paramount importance when knowing how to appropriately deal with the wide array of materials handled including, solids, liquids, volatile materials, sticky solids, oils, and gums as well as hazardous, flammable, hygroscopic and toxic compounds.

Customers can specify not only the quantity of material but also the exact vial and cap or plate for their specific application. The service provides enormous savings from a time perspective as researchers do not spend their valuable time on weighing hundreds of compounds or getting them into the correct format for their assay. It also dramatically reduces disposal costs since the exact amount of material required can be ordered rather than needing to order e.g. 100 g of material when only 0.1 g is needed for the experiment.

The high throughput analytical chemistry component of the company allows rapid validation that compounds are the correct material at the desired purity. While controlled storage conditions minimize degradation, customers may use this service to validate that the material they sent to outsourcing partner originally was correct and pure. Subsequently the service allows re-evaluation of compounds that may have decomposed during long term storage. The purification services complement the analytical services by allowing cost effective, environmentally friendly recovery of partially degraded reactive intermediates and HTS compounds at a fraction of the cost of synthesizing or purchasing these materials.

Conferences

There are several conferences related to compound management. The best known is Compound Management & Integrity [6] although many chemistry and pharmaceutical conferences include talks or specific sections on the topic.

Related Research Articles

Combinatorial chemistry comprises chemical synthetic methods that make it possible to prepare a large number of compounds in a single process. These compound libraries can be made as mixtures, sets of individual compounds or chemical structures generated by computer software. Combinatorial chemistry can be used for the synthesis of small molecules and for peptides.

<span class="mw-page-title-main">Reagent</span> Substance added to a system to cause a chemical reaction

In chemistry, a reagent or analytical reagent is a substance or compound added to a system to cause a chemical reaction, or test if one occurs. The terms reactant and reagent are often used interchangeably, but reactant specifies a substance consumed in the course of a chemical reaction. Solvents, though involved in the reaction mechanism, are usually not called reactants. Similarly, catalysts are not consumed by the reaction, so they are not reactants. In biochemistry, especially in connection with enzyme-catalyzed reactions, the reactants are commonly called substrates.

Cytotoxicity is the quality of being toxic to cells. Examples of toxic agents are toxic metals, toxic chemicals, microbe neurotoxins, radiation particles and even specific neurotransmitters when the system is out of balance. Also some types of venom, e.g. from the puff adder or brown recluse spider are toxic to cells.

An assay is an investigative (analytic) procedure in laboratory medicine, mining, pharmacology, environmental biology and molecular biology for qualitatively assessing or quantitatively measuring the presence, amount, or functional activity of a target entity. The measured entity is often called the analyte, the measurand, or the target of the assay. The analyte can be a drug, biochemical substance, chemical element or compound, or cell in an organism or organic sample. An assay usually aims to measure an analyte's intensive property and express it in the relevant measurement unit.

<span class="mw-page-title-main">Drug discovery</span> Pharmaceutical procedure

In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.

Cheminformatics refers to the use of physical chemistry theory with computer and information science techniques—so called "in silico" techniques—in application to a range of descriptive and prescriptive problems in the field of chemistry, including in its applications to biology and related molecular fields. Such in silico techniques are used, for example, by pharmaceutical companies and in academic settings to aid and inform the process of drug discovery, for instance in the design of well-defined combinatorial libraries of synthetic compounds, or to assist in structure-based drug design. The methods can also be used in chemical and allied industries, and such fields as environmental science and pharmacology, where chemical processes are involved or studied.

<span class="mw-page-title-main">Laboratory robotics</span> Using robots in biology or chemistry labs

Laboratory robotics is the act of using robots in biology, chemistry or engineering labs. For example, pharmaceutical companies employ robots to move biological or chemical samples around to synthesize novel chemical entities or to test pharmaceutical value of existing chemical matter. Advanced laboratory robotics can be used to completely automate the process of science, as in the Robot Scientist project.

<span class="mw-page-title-main">High-throughput screening</span> Drug discovery technique

High-throughput screening (HTS) is a method for scientific discovery especially used in drug discovery and relevant to the fields of biology, materials science and chemistry. Using robotics, data processing/control software, liquid handling devices, and sensitive detectors, high-throughput screening allows a researcher to quickly conduct millions of chemical, genetic, or pharmacological tests. Through this process one can quickly recognize active compounds, antibodies, or genes that modulate a particular biomolecular pathway. The results of these experiments provide starting points for drug design and for understanding the noninteraction or role of a particular location.

<span class="mw-page-title-main">Medicinal chemistry</span> Scientific branch of chemistry

Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacy involved with designing and developing pharmaceutical drugs. Medicinal chemistry involves the identification, synthesis and development of new chemical entities suitable for therapeutic use. It also includes the study of existing drugs, their biological properties, and their quantitative structure-activity relationships (QSAR).

A chemical compound microarray is a collection of organic chemical compounds spotted on a solid surface, such as glass and plastic. This microarray format is very similar to DNA microarray, protein microarray and antibody microarray. In chemical genetics research, they are routinely used for searching proteins that bind with specific chemical compounds, and in general drug discovery research, they provide a multiplex way to search potential drugs for therapeutic targets.

High-content screening (HCS), also known as high-content analysis (HCA) or cellomics, is a method that is used in biological research and drug discovery to identify substances such as small molecules, peptides, or RNAi that alter the phenotype of a cell in a desired manner. Hence high content screening is a type of phenotypic screen conducted in cells involving the analysis of whole cells or components of cells with simultaneous readout of several parameters. HCS is related to high-throughput screening (HTS), in which thousands of compounds are tested in parallel for their activity in one or more biological assays, but involves assays of more complex cellular phenotypes as outputs. Phenotypic changes may include increases or decreases in the production of cellular products such as proteins and/or changes in the morphology of the cell. Hence HCA typically involves automated microscopy and image analysis. Unlike high-content analysis, high-content screening implies a level of throughput which is why the term "screening" differentiates HCS from HCA, which may be high in content but low in throughput.

Hit to lead (H2L) also known as lead generation is a stage in early drug discovery where small molecule hits from a high throughput screen (HTS) are evaluated and undergo limited optimization to identify promising lead compounds. These lead compounds undergo more extensive optimization in a subsequent step of drug discovery called lead optimization (LO). The drug discovery process generally follows the following path that includes a hit to lead stage:

A chemical library or compound library is a collection of stored chemicals usually used ultimately in high-throughput screening or industrial manufacture. The chemical library can consist in simple terms of a series of stored chemicals. Each chemical has associated information stored in some kind of database with information such as the chemical structure, purity, quantity, and physiochemical characteristics of the compound.

High throughput biology is the use of automation equipment with classical cell biology techniques to address biological questions that are otherwise unattainable using conventional methods. It may incorporate techniques from optics, chemistry, biology or image analysis to permit rapid, highly parallel research into how cells function, interact with each other and how pathogens exploit them in disease.

Chemoproteomics entails a broad array of techniques used to identify and interrogate protein-small molecule interactions. Chemoproteomics complements phenotypic drug discovery, a paradigm that aims to discover lead compounds on the basis of alleviating a disease phenotype, as opposed to target-based drug discovery, in which lead compounds are designed to interact with predetermined disease-driving biological targets. As phenotypic drug discovery assays do not provide confirmation of a compound's mechanism of action, chemoproteomics provides valuable follow-up strategies to narrow down potential targets and eventually validate a molecule's mechanism of action. Chemoproteomics also attempts to address the inherent challenge of drug promiscuity in small molecule drug discovery by analyzing protein-small molecule interactions on a proteome-wide scale. A major goal of chemoproteomics is to characterize the interactome of drug candidates to gain insight into mechanisms of off-target toxicity and polypharmacology.

Pan-assay interference compounds (PAINS) are chemical compounds that often give false positive results in high-throughput screens. PAINS tend to react nonspecifically with numerous biological targets rather than specifically affecting one desired target. A number of disruptive functional groups are shared by many PAINS.

<span class="mw-page-title-main">Aurora Biosciences</span>

Aurora Biosciences was a biotechnology company founded in 1995 in San Diego to commercialize fluorescence assays based on Roger Y. Tsien's discoveries concerning green fluorescent protein and its uses in basic research - work for which Tsien eventually won the 2008 Nobel Prize in chemistry along with two other chemists.

The European Lead Factory is a public-private partnership that aims to accelerate early drug discovery in Europe. The European Lead Factory is funded by the Innovative Medicines Initiative and consists of a pan-European consortium that includes 7 pharmaceutical companies as well as partners from academia and small and medium-sized enterprises (SMEs).

<span class="mw-page-title-main">Fluorescence polarization immunoassay</span> Class of invitro biochemical test

Fluorescence polarization immunoassay (FPIA) is a class of in vitro biochemical test used for rapid detection of antibody or antigen in sample. FPIA is a competitive homogenous assay, that consists of a simple prepare and read method, without the requirement of separation or washing steps.

<span class="mw-page-title-main">James Inglese</span> American biochemist

James Inglese is an American biochemist, the director of the Assay Development and Screening Technology laboratory at the National Center for Advancing Translational Sciences, a Center within the National Institutes of Health. His specialty is small molecule high throughput screening. Inglese's laboratory develops methods and strategies in molecular pharmacology with drug discovery applications. The work of his research group and collaborators focuses on genetic and infectious disease-associated biology.

References

  1. ↑ Archer JR (December 2004). "History, evolution, and trends in compound management for high throughput screening". Assay and Drug Development Technologies. 2 (6): 675–681. doi:10.1089/adt.2004.2.675. PMID   15674025.
  2. ↑ Yates I (March 2003). "Compound management comes of age" (PDF). Drug Discov World. 2: 35–42.
  3. ↑ Handen JS (2005). "Compound Management". Industrialization of Drug Discovery. CRC Press. ISBN   9780824723910.
  4. ↑ Wedin R (January–February 1999). "Taming the monster haystack: The challenge of compound management". Modern Drug Discovery. 2: 47–53.
  5. ↑ Yasgar A, Shinn P, Jadhav A, Auld D, Michael S, Zheng W, et al. (April 2008). "Compound Management for Quantitative High-Throughput Screening". Jala. 13 (2): 79–89. doi:10.1016/j.jala.2007.12.004. PMC   2390859 . PMID   18496600.
  6. ↑ "Compound Management & Integrity 2009". Chemistry Conferences. Archived from the original on 25 December 2008.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.